Abbott Launches Trial for New Mitral Valve System
The CROWN-MV study evaluates a minimally invasive valve replacement option for patients ineligible for conventional surgery.
Updated on Oct. 31, 2026 in Heart Disease
Live Poll
Do you believe new medical device trials are effectively expanding treatment options for high-risk patients?
Abbott has initiated the CROWN-MV pivotal clinical trial to assess the safety and effectiveness of its Cephea Mitral Valve System. This study targets patients with symptomatic mitral valve disease who cannot undergo open-heart surgery or standard transcatheter repair.
Why it matters
The system offers a potential treatment breakthrough for individuals who currently lack viable surgical options for heart valve repair. By using a minimally invasive approach, the device may improve health outcomes for high-risk patients with complex mitral valve conditions.
The clinical trial aims to enroll up to 585 participants in the United States, Canada, and Europe. Researchers intend to build upon data from a 30-day early feasibility study previously conducted for the device.
The players
Abbott
This global healthcare company develops medical devices, diagnostics, and branded generic medicines.
Ascension Via Christi Hospital
This medical facility located in Wichita, Kansas, serves as the site for the first patient enrollment in the CROWN-MV clinical trial.
The details
The Cephea device is a bioprosthetic valve designed to replace diseased mitral valves by being delivered via catheter through a leg vein. Once guided to the heart, the valve is implanted and expanded inside the existing structure to restore proper blood flow.
Timeline
October 31, 2026 – November 3, 2026: The 38th Transcatheter Cardiovascular Therapeutics annual scientific symposium takes place.
November 1, 2026: Researchers present early feasibility study data at 2:57 p.m.
Health Landscape
This research follows the standard trajectory of clinical validation often showcased at the Transcatheter Cardiovascular Therapeutics annual scientific symposium. It represents an evolution in transcatheter medicine by targeting patient populations previously excluded from less invasive procedures.
This development could eventually provide a new, less invasive treatment option for patients currently considered ineligible for open-heart surgery. It highlights potential future advancements in managing symptomatic mitral valve disease for those with limited medical alternatives.
The takeaway
The initiation of this pivotal trial signals a broader shift toward expanding transcatheter solutions for complex heart conditions. Patients should consult with cardiologists about whether emerging trials like CROWN-MV align with their specific health needs.
Further reading
For more information on current treatment options, visit the Heart Disease section.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Do you believe new medical device trials are effectively expanding treatment options for high-risk patients?
